Phase 2 Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People whose kidneys are working at a reduced but not severely low level, based on a specific kidney function test result (eGFR between 30 and 90) at screening
- People with a certain level of protein in their urine, within a specific range, at screening (confirm with trial site for exact values)
- People with a history of high blood pressure, with blood pressure readings above certain levels at both the screening visit and the randomisation visit
- People who have been taking a stable, maximum tolerated dose of one specific type of blood pressure medication (either an ACE inhibitor or an ARB, but not both) for at least 4 weeks before screening — unless this is not medically appropriate for them
- People whose blood potassium level falls within a specific healthy range at screening, with the exact range depending on their kidney function result
- Female participants whose use of contraception is consistent with local regulations for people taking part in clinical studies
Who may not be able to join:
- People with very high blood pressure readings at screening (systolic above 180 mmHg or diastolic above 110 mmHg)
- People who have had a high blood potassium level (5.5 mmol/L or above) within the 3 months before screening
- People with a low blood sodium level at the screening visit
- People with Type 1 diabetes, or people with poorly controlled Type 2 diabetes (based on a blood sugar control test result) at screening
- People with the most severe category of heart failure symptoms (classified as New York Heart Association Class IV) at screening
- People who have taken certain medications that affect potassium levels — including some heart and kidney medications — within 4 weeks before screening (confirm with trial site for the full list)
- People who have had a stroke, mini-stroke, heart attack, certain heart procedures or surgeries, or a hospital admission for worsening heart failure within the 3 months before joining the trial
- People with severe liver disease (classified as Child-Pugh Class C) based on documented medical history
- People with a documented history of adrenal insufficiency (a condition affecting the adrenal glands)
- People who have been on dialysis for any reason within the 3 months before screening
- People who have had an acute (sudden) kidney injury within the 3 months before screening
- People currently taking certain medications that are not permitted during this trial (confirm with trial site for the full list)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.